HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lauder Focuses On Millennials In Turnaround Of Namesake, Clinique

This article was originally published in The Rose Sheet

Executive Summary

Firm expects to record modest gains for its Estee Lauder and Clinique brands in fiscal 2016, after slight declines projected for both in the current fiscal year, and is innovating for and engaging with millennials to drive momentum. During Lauder's recent third-quarter earnings call, leadership highlighted forthcoming product launches expected to appeal to the younger generation while continuing to serve core consumers.

You may also be interested in...



Fragrance Creators Association Readies New Consumer Website To Cap ‘Year For The Public’

Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.

FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.

US House Cosmetics Hearing: Preemption, FDA Ingredient Review Could Be Regulatory Reform Snags

Federal preemption of state and local requirements that differ from federal mandates came up repeatedly at the House Energy & Commerce Health Subcommittee’s 4 December cosmetics hearing. Meanwhile, both NGO and industry stakeholders generally support FDA review of cosmetic ingredients, but the details of such a framework likely will be contentious as work progresses.

Related Companies

UsernamePublicRestriction

Register

RS019496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel